| scholarly article | Q13442814 |
| P50 | author | Hideo Baba | Q88403580 |
| Shigeki Nakagawa | Q88464273 | ||
| P2093 | author name string | Katsunori Imai | |
| Hirohisa Okabe | |||
| Hiromitsu Hayashi | |||
| Yukiharu Hiyoshi | |||
| Tatsunori Miyata | |||
| Akira Chikamoto | |||
| Hidetoshi Nitta | |||
| Kota Arima | |||
| Yo-Ichi Yamashita | |||
| Yuki Kitano | |||
| Naoki Umezaki | |||
| P2860 | cites work | Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche | Q24606366 |
| Targeting ECM Disrupts Cancer Progression | Q26779300 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis | Q28236828 | ||
| Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach | Q33556245 | ||
| Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration | Q33969329 | ||
| Gene expression in fixed tissues and outcome in hepatocellular carcinoma. | Q34235518 | ||
| CaMKII Inhibitor KN-62 Blunts Tumor Response to Hypoxia by Inhibiting HIF-1α in Hepatoma Cells | Q34382055 | ||
| A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration | Q35107005 | ||
| Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma | Q35619104 | ||
| Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling | Q35933347 | ||
| Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. | Q36000813 | ||
| Molecular mechanisms mediating metastasis of hypoxic breast cancer cells | Q36254122 | ||
| Lysyl oxidase is associated with increased thrombosis and platelet reactivity. | Q36700494 | ||
| Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis | Q36788468 | ||
| LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome | Q36946751 | ||
| The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. | Q37126990 | ||
| Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson's Disease | Q37545889 | ||
| Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects | Q38032886 | ||
| Prevention of hepatitis C virus infection and liver cancer. | Q38134547 | ||
| Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis | Q38687306 | ||
| Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition | Q38726399 | ||
| Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone | Q38741210 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia | Q38861074 | ||
| Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. | Q38973071 | ||
| Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells | Q39043505 | ||
| Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex. | Q39187272 | ||
| Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development | Q39339193 | ||
| Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts | Q39396200 | ||
| Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy | Q39846654 | ||
| Survival impact of lymphocyte infiltration into the tumor of hepatocellular carcinoma in hepatitis B virus-positive or non-B non-C patients who underwent curative resection | Q40127743 | ||
| Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. | Q40252283 | ||
| The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. | Q40654117 | ||
| Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma | Q41690535 | ||
| Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma | Q42254863 | ||
| Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation | Q42263202 | ||
| Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. | Q42992540 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy | Q45332139 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| Combination of Gene Expression Signature and Model for End-stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis | Q47439747 | ||
| Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis | Q47931449 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. | Q50997346 | ||
| miR30a inhibits LOX expression and anaplastic thyroid cancer progression. | Q51026708 | ||
| Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers. | Q53133741 | ||
| P433 | issue | 6 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 2033-2043 | |
| P577 | publication date | 2019-04-18 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma | |
| P478 | volume | 110 |
Search more.